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Abstract
In 1993, a gene silencer known as lin-4 was first discovered in Caenorhabditis 
elegans and demonstrated to be critical for larval development. Lin-4 belongs to a 
family of signaling molecules known as non-protein coding microRNAs (miRNAs) 
which are not only highly conserved in humans, but also involved in the funda-
mental processes of oncogenesis. While miRNAs are not translated to proteins 
themselves, they are capable of regulating the expression and translation of other 
genes thus affecting a multitude of biological and pathological pathways as well as 
those essential to the malignant landscape. The aim of this chapter is to explore the 
diverse roles of miRNAs in the context of breast cancer. Following a brief overview 
of miRNA biogenesis, this chapter covers the production of miRNAs by tumor cells 
and stromal cells, onco-suppressor miRNAs, use as therapeutics, contribution to 
therapeutic resistance, and finally their emerging role as biomarkers.
Keywords: microRNAs (miRs), breast cancer epigenetic alteration, microRNA-based 
therapy, miRNA pharmacogenomics, miRSNPs, miR-polymorphisms, clinical trials
1. Introduction
A gene silencer known as lin-4 was first discovered in Caenorhabditis elegans and 
demonstrated to be critical for larval development [1]. Lin-4 belongs to a family of 
signaling molecules known as non-protein coding microRNA (miRNAs) which are 
not only highly conserved in humans, but also involved in the fundamental processes 
of oncogenesis [2]. Approximately 2000 miRNAs are present in the human genome [3]. 
While miRNAs are not translated into proteins themselves, they are implicated in the 
regulation of 30% of all genes and are thereby capable of regulating the expression 
and translation of other genes influencing a multitude of biological and pathological 
pathways [4]. This chapter explores the diverse roles of miRNAs in the most frequent 
cancer among women in the world: breast cancer (BC). BC impacts 2.1 million women 
yearly [5] and it also causes the greatest number of cancer-related deaths among 
women. Early detection and diagnosis are critical to survival. In the context of BC, 
miRNAs are dynamically regulated implicating their use in diagnosis, prognosis and 
tracking of drug efficacy during treatment. Following a brief overview of miRNA 
biogenesis, this chapter covers the production of miRNAs by tumor cells, onco-sup-
pressor and tumor-suppressor miRNAs, their contribution to therapeutic resistance, 
therapeutic miRNAs (as well as therapeutics targeting of miRNAs), and finally their 
emerging role as biomarkers for BC prognosis, treatment responsiveness and efficacy.
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2. MiRNA biogenesis and mechanisms of action
Since 1993, researchers have proceeded to learn that miRNAs were of ancient 
evolutionary origins. Single stranded, non-protein coding miRNAs with genetic 
suppression activities were found in algae, plants, invertebrates, vertebrates and 
even viruses [6]. Further characterization has revealed that miRNAs are not only 
critical for normal human development, but their aberrant expression is associated 
with diseases such as cancer [7, 8].
The miRNAs are encoded by genetic sequences which may be located within 
the introns of protein coding genes as well as in the exons and introns of long 
noncoding RNAs, and even intergenic regions [9]. According to the miRIAD 
database, 1157 (61.5%) miRNAs are intragenic (169 exonic and 988 intronic) and 
724 (38.5%) are intergenic [10]. MiRNA’s are single-stranded RNA transcripts 
that are transcribed from DNA sequences and are usually around 22 nucleotides 
in length. They often form distinct secondary folding conformational motifs. 
Most miRNAs are first transcribed into primary miRNAs (pri-miRNAs) and 
processed into precursor miRNAs (pre-miRNAs) and mature miRNAs. Usually 
they bind to the 3′-untranslated region (UTR) of target mRNAs to suppress their 
target’s expression by inhibiting its translation. However, they can also interact 
with coding sequences, the 5′UTR and gene promoter regions. Though less com-
mon, some are involved in the translation activation and stabilization of target 
transcripts. Furthermore, the shuttling of miRNAs between different cellular 
compartments can also control rates of transcription and translation of their 
targets.
In the canonical pathway of miRNA biogenesis, RNA polymerase II transcribes 
miRNAs into primary miRNAs (pri-miRNAs) greater than 200 nucleotides long. 
Pri-mRNAs are then cleaved into pre-mRNAs by the RNAse III enzyme, Drosha 
with the help of double stranded RNA binding proteins Pasha and DiGeorge 
Syndrome Critical Region 8 (DGCR8). The 60–70 nucleotides long pre-mRNAs are 
then exported out of the nucleus and into the cell cytoplasm by exportin-5 and Ran 
GTPase. Once in the cytoplasm, pre-mRNAs are cleaved by the RNAse III enzyme 
Dicer which removes hairpin loops resulting in miRNA duplexes composed of a 
guide strand and a passenger strand. The passenger strand is discarded and the 
guide strand associates with Argonaute 2 (Ago2) to form the RNA-induced silenc-
ing complex (RISC) which brings the miRNA to its target mRNA. A 6–8 nucleotide 
sequence on the miRNA, referred to as the “seed sequence” locates the correspond-
ing sequence of the target mRNA. A double stranded complex is formed which 
impedes the ribosome from translating the target [11]. Imperfect complementarity 
between the seed sequence and the target mRNA can also cause target degradation 
indirectly via deadenylation at the 3′-UTR. Non-canonical miRNA biogenesis is 
less common and can generally be grouped into Drosha/DGCR8-independent and 
Dicer-independent pathways which are outside the scope of this chapter. In addition 
to the inhibition of target miRNAs, there is evidence indicating that some miRNAs 
directly increase target translation via recruitment of protein synthesis complexes 
to the translation initiation region. Alternatively, target mRNA expression can 
also be increased due to inhibition of modulating repressors that block transla-
tion. Moreover, some miRNAs enhance ribosome biogenesis resulting in increased 
protein synthesis [12].
In summary, miRNA biogenesis is a multi-step process that requires various 
enzymes and shuttling proteins to reach a final product. Mature miRNAs are either 
stable molecules with half-lives of greater than 24 h or they display shorter half-lives 
of less than 12 h, depending on the functionality of the product [13]. More on the 
regulation of miRNA expression is discussed in the next section.
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3. Regulation of miRNA expression
In general, just as protein-coding genes are regulated by transcription factors 
(TF), TFs are one of the central ways by which miRNA expression is regulated. 
Tissue and developmental stage specific TFs can control the transcription of miRNA 
genes. Many miRNAs and TFs form autoregulatory loops, in which they mutually 
regulate each other [14]. In addition, various physiological and pathological stimuli, 
such as steroid hormones, retinoids, hypoxia, interferons, stress, as well as estro-
gen, can affect miRNA expression [15]. Finally, while transcription regulates the 
magnitude of miRNA expression, decay rates influence miRNA dynamic regula-
tion. Slow decay leads to a high level of accumulation while fast decay leads quick 
changes in miRNA expression levels implying that fast turnover may be involved in 
transient biological processes.
Epigenetic mechanisms are heritable changes in gene expression that occur with-
out any modifications in the DNA sequence itself and include DNA methylation and 
histone modifications as well as miRNAs themselves [16]. The covalent binding of 
methyl groups to cytosine bases located among CpG dinucleotide sequences is the 
major modification of eukaryotic genomes which results in down regulation of gene 
expression. DNA methylation controls embryonic cell fate lineages and prevents 
reversion to an undifferentiated state [17]. Frequency of methylation is nearly one 
order of magnitude higher in human miRNA genes compared to the methylation 
of other protein-coding genes [18, 19]. This indicates strict epigenetic control of 
miRNA expression and also reveals how epigenetic changes in cancer cells can lead 
to dysregulated expression of miRNAs by cancer cells.
Genome variations include genetic mutations and polymorphisms; defined as 
a DNA variation in which a possible sequence is present in at least 1% of people. 
Single nucleotide polymorphisms (SNPs) constitute approximately 1% of the 
human genome. SNPs contribute to phenotypic diversity within a species as well 
as disease susceptibility. MiRSNPs/miR-polymorphisms are a new mechanism and 
novel class of functional SNPs. As miRNA molecular interactions with their targets 
are affected via base pairing as well as genetic variation, such as changes in genome 
sequence; which influences binding energy and annealing strength, SNPs can result 
in no change, off target or absence of miRNA binding to the predicted target [20]. 
Carcinogens such as those from cigarettes, dietary elements and other foreign 
chemical toxicities referred to as “xenobiotics,” can also affect miRNA expression. 
Importantly, many more changes in miRNA expression were observed in cancer-
target tissues than in the non-target tissues following acute or chronic exposure 
to carcinogens thus implicating their use as potential biomarkers for exposure 
to xenobiotics [21]. Finally, circadian rhythm control of miRNA expression has 
significant consequences for circadian timing as some miRNAs have promoter 
sequences inducible by circadian clock proteins. Moreover, some miRNAs can even 
be regulated by light and dark cycles which confer important rhythmic expressions 
in organs such as the liver and heart [22].
In summary, miRNA regulation is similar to other protein coding gene regula-
tion as changes in expression can occur based on the presences or exposure to TFs, 
genetic polymorphisms, epigenetic factors, xenobiotics and carcinogens. How 
miRNA expression is regulated in the context of BC is discussed in the next section.
4. miRNAs (miRs) production by breast cancer cells
As summarized above, TF, SNPs, epigenetics, hormones and xenobiotics all 
affect the regulation of miRNAs; therefore, it is not surprising that breast cancer 
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(BC) leads to significant, dynamic changes in miRNA expression both by tumor 
cells and by surrounding stromal cells. This section describes BC tumor cell produc-
tion of miRNAs as well as the surrounding non-cancerous stromal cells. In general, 
miRNAs either support or suppress tumorigenesis and are often dysregulated due 
to tumor-specific epigenetic changes. Likewise, tumor secreted factors such as exo-
somes and cytokines can also lead to aberrant signaling in the surrounding stromal 
cells. Furthermore, while all BCs begin in the breast, there are many subtypes which 
are named to reflect their particular molecular pathogenesis. Subtype diagnosis 
can help select appropriate therapies. Likewise, aberrant regulation of miRNAs can 
be subtype specific. Therefore, this section begins with a brief overview of cancer 
subtypes.
Breast carcinoma can begin either in the ducts or the lobules and as such, 
termed either ductal carcinoma in situ (DCIS), or lobular carcinoma in situ 
(LCIS). Both can either stay contained to the area or travel to surrounding tissue 
and lymph nodes in which case the clinical diagnosis is either invasive ductal car-
cinoma (IDC) or invasive lobular carcinoma (ILC). IDC is the most common type 
of BC (50–75%) followed by ILC (5–15%) [23]. Rare BC is characterized by tumor 
origination in the mucinous, papillary, medullary or cribriform compartments of 
the breast [24]. Metastasis of breast cancer to other organs is the main cause of 
mortality and up to 5% of patients will already have experienced metastasis at the 
time of diagnosis [25].
MiRNA microarray performed on 1542 breast tissue samples procured via the 
Molecular Taxonomy of Breast Cancer International Consortium and the Akershus 
University Hospital (AHUS) revealed that no miRNAs were differentially expressed 
in DCIS patients relative to IDC, supporting the idea that miRNA dysregulation 
occurs at an early stage of BC development [26]. Among the invasive subtypes, 
however, expression of seven miRNAs was consistently downregulated, including 
tumor suppressors let-7c-5p, miR-125b-5p, miR140-3p, miR-145-3p, miR-145-5p, 
miR-193a-5p, and miR378a-3p while expression of four oncogenic miRNAs was 
consistently upregulated including miR-106b-5p, miR-142, miR-342-3p, and 
miR425-5p. Taken together these miRNAs may significantly contribute to the 
transition to an invasive BC subtype [26].
While Bloom and Richardson’s histologic grading system which was modified 
by Elston and Ellis in 1991 is the most commonly used system to gain prognostic 
insight, hormone receptors status, tumor size, nodal status and whether tumorous 
cells have invaded the lymph or blood vessels is also considered during initial diag-
nosis. Hormone receptor statuses including estrogen receptor (ER) and progester-
one receptor (PR) as well as the tyrosine kinase receptor, human epidermal growth 
receptor type two (HER2) are always measured on newly diagnosed invasive BCs. 
Subtypes are identified via immunohistochemical staining for hormone receptors, 
HER2 expression status, and Ki-67 proliferation index as: luminal A (ER-positive 
and/or PR-positive, HER2-negative, low proliferation), luminal B (ER-positive 
and/or PR-positive, HER2-negative, high proliferation; or hormone receptor (HR)-
positive and HER2-positive), HER2-positive (HR-negative and HER2-positive) 
and finally TNBC type (HR-negative and HER2-negative) [27]. ER+ breast cancer 
subtype is particularly prevalent in postmenopausal women taking hormone 
replacement therapy (HRT) which activates the transcription factor estrogen 
receptor alpha (ERα) which promotes the expression of numerous oncogenic 
genes. While ERα-signaling is targeted by miRNAs for degradation, aberrant 
activation of this receptor leads to aberrant expression of miRNAs controlled by 
ERα-signaling [28].
Several miRNAs are both tissue and cancer specific. As the primary role of 
miRNA is to decrease target mRNA expression, miRNAs that are upregulated by 
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cancerous cells are often those that support cancer growth and are referred to as 
oncomiRs. miR-10b, miR-21 and miR-155 are well characterized oncomiRs in BC 
[29]. Their main role is to downregulate tumor suppressor genes which results in 
the promotion of cancer cell proliferation, de-differentiation and invasion [30]. BC 
cells also produce less tumor-suppressor miRNAs (miR-31, miR-125b, miR-200 and 
miR-205) which downregulate oncogenic proteins. Cancer-initiating cells (CSCs) 
were first isolated from breast cancer tumors and are considered the seed-cells of 
tumor development [31]. While CSCs are similar to normal somatic stem cells in 
that they are capable of asymmetric cell division and the efflux of small molecules, 
they have more phenotypic plasticity. The family of miRNAs known as let-7 was 
demonstrated to be a master regulator of self-renewal and tumor-seeding ability 
[32]. Likewise, the process of epithelial to mesenchymal transition (EMT) which 
enables tumorigenicity and invasion, was facilitated via transforming growth factor 
β2 (TGF-β2) and Zeb1 transcription factor mediated repression of the miR-200 and 
miR-141; two miRNAs which are responsible for epithelial differentiation [33].
In summary, reflecting the cancer cells aim of aberrant, dysregulated gene 
expression needed for tumor cell survival and proliferation, a global downregula-
tion of all miRNAs is observed in cancer. In tumor cells, the main mechanism by 
which global miRNA production is suppressed is via the upregulation of miRNAs 
that target the crucial miRNA biogenesis enzyme Dicer, miR-103 and miR-107 [34]. 
Likewise, chromatin remodeling that results in an increase in miRNAs that sup-
port EMT and self-renewal rather than continuation of a differentiated cell type is 
observed [35].
5. miRNAs affecting breast cancer chemotherapy efficacy and resistance
Chemoresistance is the primary cause of treatment failure in breast cancer. 
Dysregulation of some miRNAs can result in increases in drug efflux, alter drug 
targets and energy metabolism, stimulate DNA repair pathways and evasion of 
apoptosis and result in loss of cell cycle control. The first BC drug was a DNA-
replication blocker called doxorubicin. Resistance to doxorubicin correlated with 
downregulation of miR-505, miR-128, and miR-145 tumor suppressors [36–41]. In 
contrast, miR-663, miR-181a, and miR-106b are oncogenic miRNAs whose down-
regulation resulted in enhancement of doxorubicin sensitivity in formerly resistant 
cells [41–43]. Like doxorubicin, cisplatin inhibits DNA replication and was also 
one of the first established therapies for BC. Upregulation of miR-345 and miR-7 
contribute to cisplatin-resistance, while miR-302b can sensitize resistant cells to 
cisplatin therapy [44, 45]. A list of miRNA expression levels and targets of BC drug 
resistant is listed in Table 1.
In addition to doxorubicin and cisplatin, efficacy of the chemotherapeutic 
agents docetaxel and paclitaxel which inhibit microtubule formation during cell 
division, can also be compromised by miRNAs. Downregulation of miR-34a, miR-
100, and miR-30c were observed in paclitaxel-resistant BC cell while the upregula-
tion of miR-129-3p was found to contribute to resistance [57–61].
In ER+ breast cancer, de novo and acquired resistance to conventional endocrine 
therapies such as aromatase inhibitors, fulvestrant and tamoxifen, can occur in 
more than 30% of patients [63]. Evidence suggests that resistance to these drugs is 
in part mediated by miRNAs. As most BC patients have high estrogen receptor-α 
(ER-α) expression, targeting ER-α signaling is a critical therapy. Resistance to 
tamoxifen, an agent which blocks interaction between estrogen and estrogen 
receptor is associated with the downregulation of the following tumor suppres-
sor miRNAs: miR-15a, miR-16, miR-214, miR-320, miR-342, miR-451, miR-873, 
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miRNA-375, miR-378a-3p, and miR-574-3p [64–71] .In contrast, oncogenic miRs: 
miR-101, miR-221/222, miR-301, and miRNAs-C19MC were highly expressed in 
tamoxifen resistant cells [72–75]. In addition, both the humanized monoclonal 
antibody targeting HER2 named trastuzumab, as well as lapatinib, which is a small-
molecule tyrosine kinase inhibitor targeting both HER2 and epithelial growth factor 
receptor (EGFR), improve therapeutic outcome but result in resistance after 1 year. 
miRNA BC therapy Targets Level Mechanism/Refs.
miR-200 Carboplatin Zeb ↓ Reverses EMT [46]
miR-345 Cisplatin MRP1 ↓ Not yet characterized [45]
miR-7
miR-302b Cisplatin E2F1 (direct) ↓ Inhibit cell cycle progression 
[44]
ATM (indirect)
miR-24 Cisplatin BimL F1H1 ↑ Promotes EMT and cancer stem 
cells [47]
miR-
106b~25 
cluster
Doxorubicin EP300 ↑ Activates EMT [43]
miR-128 Doxorubicin Bmi-1 ABCC5 ↓ Increases apoptosis [48]
miR-145 Doxorubicin MRP1 ↓ Induces intracellular 
doxorubicin accumulation [36]
miR-181a Doxorubicin Bcl-2 ↓ Increases apoptosis [41]
miR-181a Doxorubicin Bax ↑ Inhibits apoptosis [49]
miR-25 Doxorubicin ULK1 ↑ Inhibits autophagy [50]
miR-326 Doxorubicin MDR-1 ↓ Downregulates MRP-1 [51]
miR-505 Doxorubicin Akt3 (indirect) ↓ Not yet investigated [37]
miR-644a Doxorubicin CTBP1 ↓ Inhibits EMT [52]
miR-663 Doxorubicin HSPG2 ↑ Inhibits apoptosis [42]
miR-129-3p Docetaxel CP100 ↑ Reduces cell cycle arrest and 
apoptosis [53]
miR-34a Docetaxel BCL-2 CCND1 ↑ Inhibit apoptosis [54]
miR-484 Gemcitabine CDA ↓ Promote proliferation and cell-
cycle redistribution [55]
miR-218 MDR Survivin ↓ Enhance apoptosis [56]
miR-100 Paclitaxel mTOR ↓ Enhance cell cycle arrest and 
apoptosis [57]
miR-125b Paclitaxel Sema4C ↓ Reverses EMT [58]
miR-125b Taxol Bak1 ↑ Inhibits apoptosis [59]
miR-30c Doxorubicin TWF1 (PTK9) VIM 
IL-11
↓ Reverses EMT [60]
Paclitaxel
miR-34a Doxorubicin HDAC1HDAC7 ↑ Inhibits autophagic cell death 
[61]
Cisplatin
Abbreviations: Expression level of miRs: upregulation (↑) or downregulation (↓) of miRNAs in breast cancer therapy. 
The reference of each miR is included in the table. Table adapted from Hu et al. [62].
Table 1. 
miRNAs involved in the regulation of common breast cancer drugs.
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Resistance to these two drugs is correlated with an upregulation of miR-21, miR-221 
and miR-375 [76–80].
The role of miRNA in chemotherapeutic resistance is associated with the modi-
fication of drug transporters which has a net effect of drug efflux out of the cell 
via exosomes as well as modifications of autophagy and apoptosis pathways which 
lead to enhanced survival, the promotion of growth factors and activation EMT 
[81]. The tumor microenvironment which consists of the surrounding stromal cells 
serve as the normal foundation upon which the deviant tumor “house” is con-
structed supplying it with blood vessels, signaling molecules and ECM. Exosomes 
transport bioactive molecules and mediate cellular communication in the tumor 
microenvironment, facilitating a more cancerous and recalcitrant milieu [82]. 
For example, exosome-derived miRNAs such as miR-222 transfer doxorubicin-
resistance by inhibiting PTEN in recipient cells, 22 miRNAs were concentrated 
in exosomes and correlated to chemotherapy resistance [83]. While the major 
function of exosomes in the context of BC and drug resistance is the shuttling of 
drugs out of the tumor, exosomes can also be bio-hacked for use as a prime chemo-
therapy delivery system [84–86].
In summary, in the context of breast cancer, tumor cells regulate miRNAs in a 
way that promotes tumor survival, growth and invasion. Aside from a global down-
regulation of most miRNAs and especially tumor suppressor miRNAs, oncogenic 
miRNAs are increased and often exported via exosomes where they are taken up by 
non-cancerous cells, transforming the local environment to a pro-cancer milieu. 
Knowing how BC cells regulate miRNAs opens the door for potential therapies that 
target oncogenic miRNAs (antagomirs) or add back tumor suppresser miRNAs 
(mimic miRNAs). The targeting of miRs in breast cancer is discussed in the follow-
ing section.
6. miRNAs as breast cancer therapy
As reviewed in this chapter, miRNAs are dynamically regulated in BC and can 
also contribute to drug resistance. Therefore, interventions that disrupt activities 
of dysregulated miRNAs offer promising targets for novel therapeutics in the 
form of mimics or antagomirs. In addition, mature miRNAs and their precursors 
can also be targeted by small molecules. In general, there are two strategies for 
targeting miRNA in BC. In the first strategy, tumor suppressor miRNAs which 
are down regulated by tumor cells can be added back to the tumor microenviron-
ment using chemically synthesized miRNA mimics which imitate endogenous 
mature double-stranded miRNA [87]. MiRNA mimics could be delivered in viral 
vectors which would allow extended expression. The second strategy is to target 
oncogenic miRNAs which are highly expressed and exported by tumor cells. In 
this strategy, oligonucleotides, locked-nucleic-acids antisense oligonucleotides 
(LNAs), miRNA sponges, multiple-target anti-miRNA antisense oligo-deoxyribo-
nucleotides (MTg-AMOs), miRNA-masking and nanoparticles are used to target 
for degradation or impede aberrantly expressed oncogenic miRNAs from reaching 
their targets [88–91].
As previously mentioned, the majority of highly expressed, dysregulated miRNAs 
in tumor cells are oncomirs, or those that support tumorigenesis, while tumor 
suppressor miRNAs are suppressed [92]. For example, miR-155 is an oncogenic 
miRNA upregulated in BC tumor tissue. Targeting of miR-155 with an antisense 
oligonucleotide (miR-155) in a BC cell line blocked proliferation and augmented 
apoptosis [93]. MiR-892b is an example of a tumor suppressor miRNA that is 
significantly downregulated in BC tissue specimens. By supplementing miR-892b 
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“mimics” in BC cells, a decrease in tumor growth, metastases rate, and angiogenesis 
was observed. MiR-892b mimic blocked impeded tumorigenesis by attenuating 
nuclear transcription factor kappa B (NF-kB) signaling [94]. Artificial miRNAs can 
also be constructed to inhibit targets that are not normally targeted by endogenous 
miRNAs. For example, a novel artificial miRNA (amiRNA) called miR-p-27-5p, 
which targets the 3′-UTR of cyclin-dependent kinase 4 (CDK4) mRNA, inhibited 
cell cycle progression via downregulation of CDK4 expression and suppression of 
retinoblastoma protein (RB1) phosphorylation [95]. Likewise, an a miRNA against 
a C-X-C motif chemokine receptor 4 (CXCR4) inserted into an expression vector 
reduced CXCR4 expression and suppressed migration and invasion of BC cells [96]. 
While in vitro experiments provide proof of concept for further development of 
miRNA targeting in oncogenic diseases, only clinical trial results can determine 
whether miRNA therapy is truly efficacious. Patents, clinical trials and biophar-
maceutical companies invested in the development of miRNA therapies are sum-
marized by Chakraborty et al, [97]. A seminal trial for miRNA replacement therapy 
took place employing the tumor suppressor miR-34 mimic (MRX34). MRX34 was 
formulated for intravenous injection using a liposome delivery system for patients 
with metastatic liver cancer. MRX34 along with dexamethasone was associated 
with safety and showed evidence of antitumor activity in a subset of patients with 
refractory advanced solid tumors [98]. However, there were adverse events in the 
trial which indicate the need for alternative approaches in formulation design and 
delivery.
In summary, there is much research to be done in the emerging field of miRNA 
therapeutics. Drug developers, pharmacists, physicians and molecular biologists 
must work together to develop novel strategies for miRNA delivery that is more 
targeted and controlled in order to mitigate off-target effects by affecting only cell 
signaling of targeted tumor cells.
7. miRNAs as breast cancer biomarkers
MiRNAs that maintain a stable presence in the serum are referred to as “cir-
culating” miRNAs. Thus, in addition to therapeutic targeting, many studies have 
reported utility of miRNAs in the context of BC as biomarkers for diagnostic, 
prognostic, or predictive of drug efficacy. In this final section, miRNAs currently 
being used as biomarkers in the context of BC are discussed.
In the context of diagnostics, the current gold standard for BC is mammography. 
However, many women avoid mammograms for fear of pain or inconvenience in 
scheduling thus rendering assays performed on less invasive, routine blood draws 
amenable to early screening for BC. Global profiling of circulating miRNAs in 
early-stage ER+ BC (n = 48) and age-matched healthy controls (n = 24) revealed a 
panel of nine miRNAs (miR-15a, miR-18a, miR-107, miR-133a, miR-139-5p, miR-
143, miR-145, miR-365 and miR-425) that discriminated between patients with 
early-stage ER+ BC and healthy controls [99]. A study in Japan performed on serum 
(n = 1280 BC, n = 2836 non-cancer controls) found a combination of five miRNAs: 
miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p, could predict 
breast cancer with a sensitivity of 97.3% overall, 98% sensitivity for early stage BC 
and a specificity of 82.9% and accuracy of 89.7% [100]. A study based in Prague 
(n = 63 early stage BC, n = 21 non cancer controls) found that several oncogenic 
miRNAs were significantly elevated in early stage BC; including: miR-155, miR-19a, 
miR-181b, and miR-24 and unsurprisingly, their expression dropped following sur-
gical resection of the tumor [101]. A study in Singapore performed global profiling 
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Source miRNA Expression/Refs DX PX PR VA
Blood miR-195, let-7 and -155 ↑ in BC [108] Y N N N
Serum miR-214 Indicates malignant 
from benign and 
healthy [109]
Y N N N
Plasma miR-127-3p, -376a, -148b, 
-409-3p, -652 and -801
↑ in BC [110] Y N N Y
Plasma miR-148b, -133a, and -409-3p ↑ in BC [111] Y N N Y
Serum miR-15a ↑ in BC [99] Y N N Y
miR-18a, -107, -425, -133a, 
-139-5p, -143, -145, and -365
↓ in BC [99]
Serum miR-484 ↑ in BC [112] Y N N Y
Serum miR-1246, -1307-3p, and 
-6861-5p
↑ in BC [100] Y N N Y
miR-4634 and -6875-5p ↓ in BC [100]
Serum miR-155, -19a, -181b, and -24 ↑ in BC [101] Y N N N
Serum miR-1, -92a, -133a, and -133b ↑ in BC [102] Y N N Y
Plasma miR-505-5p, -125b-5p, -21-
5p, and -96-5p
↑ in BC [113] Y N N Y
Serum let-7c ↓ in BC [103] Y N N N
Serum miR-182 ↑ in BC [114] Y N N N
Blood miR-138 ↑ in BC [115] Y N N N
Serum miR-155 Correlates w/PR 
status [116]
Y N N N
Serum miR-21, -126, -155, -199a, 
and -335
Associated w/
histological tumor 
grade and sex 
hormone receptor 
expression [117]
Y N N N
Serum; 
Plasma
miR-4270, -1225-5p, -188-5p, 
-1202, -4281, -1207-5p, 
-642b-3p, -1290, and -3141
↑ in BC and correlates 
w/stage and 
molecular subtype 
[118]
Y N N Y
Serum miR-202 and let-7b ↑ expression in BC 
and correlates w/
tumor aggressive and 
overall survival [119]
Y Y N N
Serum miR-148b-3p and -652-3p ↓ in the BC [120] Y Y N Y
miR-10b-5p ↑ levels correlate w/
poor prognosis [120]
Serum miR-18b, -103, -107, and -652 Associated w/tumor 
relapse and overall 
survival in TNBC 
[105]
Y Y N Y
Plasma miR-10b and -373 ↑ in breast cancer w/
LN metastasis [121]
Y Y N Y
Serum miR-10b, 34a, and -155 Correlates w/
tumor stage and/or 
metastasis [122]
Y Y N N
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of miRNA expression in BC tumor tissue, non-tumor tissue and serum samples 
obtained from BC patients (n = 132) and from healthy controls (n = 123) revealed 
miR-1, miR-92a, miR-133a and miR-133b as significantly upregulated diagnostic 
markers in BC sera [102]. In addition to upregulation of oncogenic miRNAs, tumor 
suppressor Let-7c was decreased in BC tissue and sera according to a study per-
formed in China (n = 90 BC, n = 64 controls) [103]. Although some studies have 
suggested that let-7 and miR-195 restoration may be therapeutic, results of Qattan 
et al. in 2017 [104] supported literature indicating that tumor cells export hsa-
miR-195 and let-7 miRNAs. While the data of this study did not generally support 
the use of these miRNAs as therapies, it suggested that these markers may be the 
most robust markers to use in a blood-based screen for the early detection of TNBC 
and luminal breast cancer [104].
The definition of a prognostic biomarker is one that indicates recurrence or 
progression; such as chance of survival, independent of the course of therapy. 
In a study based in Germany, pre-operative serum (n = 102) and post-operative 
serum (n = 34) of BC patients was compared to healthy women (n = 37) or those 
with benign breast disease (n = 26). The mean follow-up time of for BC patients 
was 6.2 years. In this study, high expression of miR-202 positively correlated with 
reduced overall survival (poor prognosis). In a European study, genome-wide 
miRNA expression profiling using serum from TNBC patients (n = 130) and healthy 
controls (n = 30), revealed a four-miRNA signature (miR-18b, miR-103, miR-107 
Source miRNA Expression/Refs DX PX PR VA
Serum miR-29b-2, miR-155, miR 
-197 and miR -205
Correlates w/tumor 
grade and metastasis 
[123]
Y Y N N
Serum miR-92a ↓ in BC, LN 
metastasis [124]
Y Y N N
miR-21 ↑ in BC, LN 
metastasis [124]
Serum miR-21-5p, -375, -205-5p, and 
-194-5p
↑ in recurrent BC 
[125]
Y Y N Y
miR-382-5p, -376c-3p, and 
-411-5p
↓ in recurrent BC 
[125]
Serum miR-34a, -93, -373, -17, and 
-155
Expression correlated 
w/metastasis and 
HER2, PR, and ER 
status [126]
Y N N N
Serum miR-125b ↑ expression in non-
responsive [127]
Y N Y N
Serum miR-122 ↓ in NR and pCR 
[128]
N N Y Y
miR-375 ↑ in NR and pCR 
[128]
Serum miR-155 ↑ in BC; ↓ post chemo 
[107]
Y N Y N
Abbreviations: DX, diagnostic; PX, prognostic; PR, predictive; VA, validated; BC, breast cancer; ddPCR, droplet 
digital PCR; DS, deep sequencing; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, 
lymph node; miRNA (miR), microRNA; PR, progesterone receptor; qRT-PCR, quantitative reverse transcriptase real-
time PCR; TNBC, triple-negative breast cancer; NR, non-relapse; pCR, Pathologic complete response.
Table 2. 
Circulating miRNAs; diagnostic, prognostic, predictive and validated biomarkers in breast cancer.
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and miR-652) that predicted tumor recurrence and overall survival [105]. While 
few studies have investigated the use of miRNA serum expression levels as a predic-
tive metric for treatment response, clinically relevant outcomes were revealed in the 
studies performed indicating the need for incentivizing investigations into miRNA 
biomarkers. For example, elevated miR-125b expression predicts poor prognosis, is 
associated with tumor size and TNM stage in HER2+ BC as well as poor responsive-
ness to paclitaxel-based neoadjuvant chemotherapy [106]. Therefore, miR-125b 
may be a potential predictor of clinical outcome, particularly in HER2+ BC patients 
receiving paclitaxel-based neoadjuvant chemotherapy. In another example, miR-155 
was significantly increased in BC patients (n  =  103) compared with healthy normal 
(n  =  55). Post-surgical resection and four cycles of chemotherapy, a subset of BC 
patient sera (n  =  29) were collected to evaluate the effects of clinical treatment on 
serum levels of candidate miRNAs. Decreased levels of circulating miR-155 post-
treatment was associated with response to therapy and stable disease [107].
In summary, the data from these studies and others suggest that BC patients 
with novel miRNA signatures correlating with poor prognosis are not receiving 
adequate treatment and should be selected for inclusion in novel randomized clini-
cal trials for the chance to receive alternative life-saving therapies. Table 2 sum-
marizes studies revealing statistically significant regulation of circulating miRNAs 
with diagnostic (DX), prognostic (PX), predictive biomarkers (PR) potential for 
BC. Some studies were validated (VA) with alternative cohorts.
8. Conclusions
In conclusion, this chapter provided an overview of the most recent studies 
describing the dynamic roles of miRNAs in the context of BC. This overview 
demonstrates that just as miRNAs are integral to maintaining normal homeosta-
sis, they are simultaneously sensitive to changes in overall physiology and local 
micro-environments thus studying them will likely lead to insight into the unique 
manifestation of BC in an individual. Given that they are actively released by tumor 
cells into the circulatory system, both monitoring and targeting miRNAs enables 
the diagnosis and monitoring of BC as well as the opportunity for the development 
of novel therapeutics. Future studies should employ well standardized methods for 
sample collection and multi-center global miRNA profiling to reveal novel nuances 
and robust results regarding miRNA signaling in the context of BC. Taken together, 
the emerging field of precision oncology may rely on understanding miRNA 
profiles.
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